Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CIRESI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.211
EU - Europa 5.140
AS - Asia 4.478
Continente sconosciuto - Info sul continente non disponibili 807
SA - Sud America 733
AF - Africa 141
OC - Oceania 10
Totale 22.520
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.023
SG - Singapore 1.580
IT - Italia 1.560
CN - Cina 1.243
RU - Federazione Russa 1.065
BR - Brasile 546
FI - Finlandia 540
VN - Vietnam 385
HK - Hong Kong 380
DE - Germania 375
PL - Polonia 265
FR - Francia 259
UA - Ucraina 250
IE - Irlanda 249
GB - Regno Unito 219
JP - Giappone 149
KR - Corea 145
BD - Bangladesh 128
SE - Svezia 103
IN - India 83
CA - Canada 82
TR - Turchia 82
AR - Argentina 70
NL - Olanda 47
MX - Messico 46
CI - Costa d'Avorio 40
IQ - Iraq 40
RO - Romania 36
ES - Italia 35
AT - Austria 32
BE - Belgio 32
CL - Cile 32
PK - Pakistan 30
ZA - Sudafrica 27
NP - Nepal 24
EC - Ecuador 21
UZ - Uzbekistan 21
MY - Malesia 20
AE - Emirati Arabi Uniti 19
SA - Arabia Saudita 19
CO - Colombia 18
ID - Indonesia 18
MA - Marocco 18
PH - Filippine 17
KE - Kenya 15
PY - Paraguay 15
JM - Giamaica 14
JO - Giordania 13
CZ - Repubblica Ceca 12
IR - Iran 12
TN - Tunisia 12
UY - Uruguay 12
CH - Svizzera 11
CR - Costa Rica 11
VE - Venezuela 11
AL - Albania 9
LB - Libano 9
AU - Australia 8
DZ - Algeria 8
EG - Egitto 8
IL - Israele 8
BG - Bulgaria 7
GR - Grecia 7
HN - Honduras 7
PE - Perù 7
SY - Repubblica araba siriana 7
TH - Thailandia 7
TW - Taiwan 7
LT - Lituania 6
DK - Danimarca 5
AM - Armenia 4
AZ - Azerbaigian 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
KZ - Kazakistan 4
MK - Macedonia 4
NI - Nicaragua 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BS - Bahamas 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
SV - El Salvador 3
AO - Angola 2
BB - Barbados 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CY - Cipro 2
EU - Europa 2
GE - Georgia 2
KG - Kirghizistan 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
RS - Serbia 2
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
BO - Bolivia 1
BW - Botswana 1
Totale 21.699
Salva come PNG Salva come JPEG
Città #
Ashburn 1.196
Fairfield 1.162
Singapore 989
San Jose 819
Woodbridge 594
Wilmington 530
Houston 514
Seattle 470
Chandler 454
Council Bluffs 396
Cambridge 380
Hong Kong 368
Ann Arbor 334
Dublin 249
Zgierz 227
Medford 197
Moscow 195
Beijing 189
Des Moines 169
Palermo 154
Tokyo 147
Santa Clara 145
Jacksonville 141
Los Angeles 140
New York 135
Nanjing 132
Princeton 125
Dallas 124
Helsinki 121
Ho Chi Minh City 112
Hanoi 111
Lauterbourg 110
Boardman 102
Frankfurt am Main 100
Dearborn 84
Altamura 80
Chicago 71
San Diego 69
Milan 66
Changsha 58
Atlanta 57
Lawrence 56
Jinan 54
Phoenix 54
Rome 52
Nanchang 51
Tulsa 50
Tianjin 46
Hebei 45
São Paulo 45
Izmir 41
Jiaxing 41
Abidjan 40
Buffalo 39
The Dalles 38
Seongnam 37
Shenyang 36
Springfield 36
London 33
Brussels 30
Ludwigshafen am Rhein 30
Ningbo 30
Falls Church 28
Orem 28
Zhengzhou 27
Da Nang 25
Redwood City 25
Santiago 25
Denver 24
Guangzhou 24
Nuremberg 23
Montreal 22
Saint Petersburg 22
Hefei 21
Rio de Janeiro 21
Columbus 20
Munich 19
Baghdad 17
Kumar 17
Amsterdam 16
Hangzhou 16
Johannesburg 16
San Francisco 16
Toronto 16
Bari 15
Shanghai 15
Taizhou 15
Warsaw 15
Basingstoke 14
Brooklyn 14
Bucheon-si 14
Frankfurt 14
Guarulhos 14
Tashkent 14
Vienna 14
Washington 14
Amman 13
Auburn Hills 13
Naples 13
San Paolo di Civitate 13
Totale 13.392
Salva come PNG Salva come JPEG
Nome #
The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium 597
Valutazione dell’insulino-sensibilità tramite clamp euglicemico iperinsulinemico in bambini in terapia sostitutiva con GH. 377
Iter diagnostico "rapido" per un caso di MEN IIb in un giovane adolescente 346
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 333
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 305
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 285
Identification of Novel Wsf1 Mutations in a Sicilian Child with Wolfram Syndrome 275
Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index 273
Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency 271
Diabete e complicanze materno-fetali in gravidanza: confronto tra pazienti con diabete tipo 1 e tipo 2 pregravidico. 263
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 262
Commento a "Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children " 260
Hepatic steatosis index in acromegaly: Correlation with insulin resistance regardless of the disease control 257
Cornea in acromegalic patients as a possible target of growth hormone action. 251
GHD come predittore di sindrome metabolica 243
OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. 241
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association? 240
Early Lung Function Abnormalities in Acromegaly. 236
Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency 236
Circulating Irisin Levels in Children with GH Deficiency before and after 1 Year of GH Treatment 230
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 230
Clamp euglicemico iperinsulinemico e test al glucagone come utili strumenti di valutazione degli effetti metabolici della terapia sostitutiva con GH. 229
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. 228
Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy 226
Commento a "The impact of real practice inappropriateness and devices' inefficiency to variability in growth hormone consumption" 224
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency 220
Rivalutazione delle caratteristiche cliniche e metaboliche di bambini con deficit isolato di ormone della crescita durante il trattamento con GH secondo la modifica alla nota 39 AIFA 217
Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency 216
Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity 215
Il c-peptide come marker principale nella storia naturale del Diabete tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze 208
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 208
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 204
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 203
The metabolic outcomes of growth hormone treatment in children are gender specific 202
Relative Hypoleptinemia in poor controlled patients with Type 1 Diabetes 198
Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. 197
Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency 195
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis 195
The Metabolic Profile in Active Acromegaly is Gender-Specific. 194
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency 194
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. 194
Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide 194
Systolic flow peak of inferior thyroid arteries in Graves’disease: A predictive parameter for the ophalmopathy development. 192
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 192
Difficoltà di identificazione della sindrome MEN2B ad esordio infantile: iter diagnostico. 192
Studio randomizzato controllato, della durata di 2 anni, sugli effetti e la sicurezza di differenti dosaggi di r-hGH, titolati sulla base dei livelli di IGF1 in pazienti con bassa statura in trattamento: considerazioni terapeutiche e farmacoeconomiche 192
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni controregolatori: ruolo del GH 190
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children 190
Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease 190
Corneal thickness in children with growth hormone deficiency: The effect of GH treatment. 188
Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. 184
Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity 183
Changes in lipid profile and adipokine levels in GH deficient children during GH replacement therapy. 182
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 182
Adrenal incidentaloma: a new contributing factor in metabolic syndrome 181
Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess 181
The lacrimal gland herniation role in the Graves’ orbitopathy 180
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 178
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 178
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis 177
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. 177
GH-suppression test in acromegaly: comparison between OGTT and chocolate test 174
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 174
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni contro regolatori. 172
Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus 172
No effect of GH/IGF-1 excess on adrenal glands in acromegalic patients 171
Leptina e adiponectina nella valutazione del compenso glicometabolico in corso di diabete mellito di tipo 1 normopeso. 171
Decreased regulatory CD4+CD25+ Treg cells in newly diagnosed type 1 diabetes 170
Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). 170
Adrenal incidentaloma: a new contributing factor in metabolic syndrome? 168
Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency 168
Buon compenso glicemico nei pazienti acromegalici affetti da diabete secondario. 166
Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4) 166
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report 162
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations 161
Clinical and metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 161
Visceral Adipose function, insulin sensitivity and secretion in active acromegaly. 160
Maggiore rischio cardiometabolico in pazienti di razza non caucasica affetti da diabete mellito di tipo 1 idiopatico rispetto alla forma autoimmune in pazienti caucasici. 157
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study 157
Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease 157
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY 156
Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment 152
Increased central corneal thickness in acromegalic patients. 149
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 149
Miglioramento clinico e metabolico in pazienti affetti da diabete mellito tipo 1 associato ad altre endocrinopatie (APS) dopo shift della terapia insulinica basale con glargine a degludec 144
Glucose metabolism in children with growth hormone deficiency 143
Adrenal morphology and function in acromegalic patients in relation to disease activity. 139
La valutazione retinica mediante Tomografia a Coerenza Ottica (OCT) nel diabete mellito tipo 1. 138
IL CONSUMO DI BEVANDE RICCHE DI ACIDO ORTOFOSFORICO COME FATTORE DI RISCHIO PER LO SVILUPPO DI IPOCALCEMIA: IL CASO DI UNA DONNA CON IPOPARATIROIDISMO POST-CHIRURGICO 138
Il c-peptide come marker principale nella storia naturale del Diabete di tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze. 136
GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy 135
Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease 135
Improved cardiovascular and cardiometabolic risk in patients with type 1 diabetes and autoimmune polyglandular syndrome switched from glargine to degludec due to hypoglycaemic variability 134
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma 131
IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH 130
Miglioramento dell'insulino-sensibilità e dell'insulino-secrezione dopo switch da terapia con glucocorticoidi tradizionali a idrocortisone "dual release" in pazienti affetti da iposurrenalismo 129
High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. 127
Modificazioni di insulino-secrezione, insulino-sensibilità e funzione adiposa durante terapia con pasireotide in un gruppo di pazienti con malattia di Cushing 127
Impact of obesity, insulin resistance and hyperandrogenism on steatosis and fibrosis risk in young females with PCOS 125
The relationship between metabolic syndrome and bone health: results of a retrospective gender specific female study. 122
Totale 19.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.295
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.081 0 0 49 62 70 70 41 80 143 190 81 295
2022/20231.537 183 229 24 160 172 250 132 103 163 13 78 30
2023/2024763 23 119 45 68 76 138 81 60 9 44 10 90
2024/20251.975 97 75 147 179 71 60 80 203 164 208 267 424
2025/20267.345 384 216 361 499 616 1.030 1.246 735 575 981 351 351
2026/20271.383 724 446 213 0 0 0 0 0 0 0 0 0
Totale 22.520